

## ANALYTICS

# How Analytics Enable Practice Transformation

OneOncology's centralized, highly skilled analytics team and their proprietary analytics platform, OneAnalytics, enable practices to monitor practice operational metrics, measure clinical quality, and optimize performance in value-based care arrangements, ultimately, equipping practices with the insights needed to thrive in a dynamic market and enable practice transformation.



### PRACTICE PERFORMANCE

In a competitive market, practices need continual insight into their performance in order to optimize operations. Through the buildout of dashboards and KPIs, practices have the capacity to track practice operations, benchmark against other practices in the network, and inform decision making at the practice, provider, and patient level in real time to create meaningful change.

#### Example analytics:

- Drug inventory
- Revenue cycle management
- Provider productivity
- Patient volume
- Payer mix
- Drug utilization
- Service line performance
- Patient case mix



### CLINICAL QUALITY

Analytics related to clinical quality are critical for delivering superior patient care and communicating your value to stakeholders like payers and employers. The ability to measure clinical performance and compare against internal and external benchmarks ensures patients receive the highest quality care and helps practices meet quality components of value-based care programs.

#### Example analytics:

- NCCN guideline adherence
- ED utilization
- Palliative care referrals
- Active treatment at end of life
- Staging completion
- Controlled substance ordering
- Pain and depression screening
- Patient satisfaction



### VALUE BASED CARE AND PRACTICE TRANSFORMATION

- Advance directive documentation

With a multitude of payers and push for value-based care, practices need to have the data and tools to be able to participate and thrive in new payment models. By consolidating quality and cost data, practices are able to tell a comprehensive story to both commercial payors and large employer groups that community oncology is the lowest cost, highest quality setting.

#### Example analytics:

- HCC coding worklist
- ED risk score and frequent flyer list
- Transitioning patients to lower-cost agents (e.g. biosimilars)
- Value Based Care program dashboards
- Hospital price transparency

CASE STUDY:

# Los Angeles Cancer Network




**PRACTICE PERFORMANCE:  
DRUG INVENTORY**

Informed with performance metrics on OneAnalytics, Los Angeles Cancer Network was able to work with the Operations Team to bring their drug inventory down from about 13 days to under 4 days, surpassing their target goal.

**Result:** Brought LACN’s drug inventory down from ~13 days to under 4 days.

**Inventory Days on Hand**



**CLINICAL QUALITY:  
PALLIATIVE CARE REFERRALS**

OneOncology’s centralized analytics platform, OneAnalytics, proactively identifies patients eligible for palliative care referrals for providers at Los Angeles Cancer Network. Equipped with this information, providers are prepared to discuss palliative care with appropriate patients at their next appointment, thus improving their care experience and outcomes.

**Result:** Providers discussed palliative care with appropriate patients at their next appointment.

**Palliative Care Referral Work List**

Practice	Next E&M Visit	Cancer Type	Metastatic Date
Los Angeles Cancer Network	7/18/2022	Lung	3/29/2022
Provider: All	7/18/2022	Lung	4/29/2022
Patient Cohort: Stage IV Lung	7/18/2022	Lung	2/9/2022
Diagnosis Type: Lung	7/18/2022	Lung	3/4/2021
Referred to palliative care: No	7/19/2022	Lung	8/26/2021
Referred to palliative care: No	7/19/2022	Lung	11/3/2020
Referred to palliative care: Yes	7/19/2022	Lung	4/13/2022
Referred to palliative care: Yes	7/19/2022	Lung	3/9/2022
Referred to palliative care: Yes	7/19/2022	Lung	2/7/2022



**VALUE BASED CARE AND PRACTICE  
TRANSFORMATION:  
TRANSITIONING PATIENTS TO BIOSIMILARS**

Since leveraging the analytics resources of OneOncology, Los Angeles Cancer Network has successfully identified and transitioned 10% more eligible patients to biosimilars, decreasing total cost of care for their patients.

**Result:** Identified and transitioned 10% more eligible patients to biosimilars.

**Percent of Likely Eligible Patients  
for Which Biosimilar Was Given**

